logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9730951 B1

PDFFull Text
Date of Patent:
Aug. 15, 2017

Filed:

May. 24, 2016

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

Applicant:

Volant Holdings Gmbh, Feusisberg, CH;

Inventors:

Joseph M. Fayad, Las Vegas, NV (US);

Jerome Schentag, Amherst, NY (US);

Assignee:

VOLANT HOLDINGS GMBH, Feusisberg, CH;

Attorneys:

Henry D. Coleman

R. Neil Sudol

Primary Examiner:

Raymond Henley, III

Int. Cl.
CPC ...
A61K 31/70 (2006.01); A61K 9/48 (2006.01); A61K 9/28 (2006.01); A61K 9/16 (2006.01); A61K 31/7004 (2006.01); A61K 45/06 (2006.01); A61K 31/00 (2006.01); A61K 38/21 (2006.01); A61K 31/7056 (2006.01); A61K 31/7072 (2006.01); A61K 35/741 (2015.01); A61K 9/20 (2006.01); A61K 31/555 (2006.01); A61K 36/05 (2006.01); A61K 36/48 (2006.01); A61K 36/8998 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7004 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/282 (2013.01); A61K 9/2846 (2013.01); A61K 31/00 (2013.01); A61K 31/555 (2013.01); A61K 31/70 (2013.01); A61K 31/7056 (2013.01); A61K 31/7072 (2013.01); A61K 35/741 (2013.01); A61K 36/05 (2013.01); A61K 36/48 (2013.01); A61K 36/8998 (2013.01); A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 45/06 (2013.01);
Abstract

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.

Find Patent Forward Citations

Loading…